Kyverna Therapeutics, Inc. (KYTX)
(Delayed Data from NSDQ)
$13.07 USD
-0.45 (-3.33%)
Updated Jun 11, 2024 04:00 PM ET
After-Market: $13.07 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
KYTX 13.07 -0.45(-3.33%)
Will KYTX be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for KYTX based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for KYTX
Kyverna Therapeutics and National Institutes of Health Co-Author Seminal Review on Cell Therapy for Autoimmunity in Nature Reviews Immunology
Kyverna Therapeutics to Present Data on 50 Patient Experience at Symposium at EULAR 2024
12 Health Care Stocks Moving In Monday's Pre-Market Session
J.P. Morgan Predicts up to 210% Gains for These 2 ‘Strong Buy’ Stocks
Buy Rating for Kyverna Therapeutics Based on KYV-101’s Clinical Progress and Financial Stability